课题基金 / 基金详情

I-Corps: Injectable extended release local anesthetic for the treatment of post-operative pain

I-Corps: Injectable extended release local anesthetic for the treatment of post-operative pain
I-Corps:用于治疗术后疼痛的注射缓释局部麻醉剂
批准号:
1946204
负责人:
Himanshu Sant
金额:
$5.0万
依托单位:
依托单位国家:
美国
项目类别:
Standard Grant
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-15 至 2020-08-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
这个i-Corps项目的更广泛的影响/商业潜力是为控制术后疼痛提供一种安全有效的非阿片类药物治疗,可以消除手术后对处方阿片类药物的需求。手术是一个关键点,患者有发展或恶化阿片类药物滥用障碍的风险。美国和世界各地的阿片类药物危机是一个重大的公共卫生问题。在美国,阿片类药物过量自1999年以来增加了两倍,阿片类药物处方数量增加了四倍。处方阿片类药物是成瘾和不良事件的主要驱动因素。目前非阿片类药物局部控制手术后疼痛的选择有限。处方阿片类药物对公共健康的影响很大,10%的患者在手术后继续长期使用,美国医疗保健系统每年花费780亿美元。每年有超过14,000人死于处方阿片类药物滥用。随着每年手术次数的增加和门诊手术的普及,改善对术后疼痛的控制可以对不断上升的医疗费用产生显著且日益增加的影响。这项i-Corps项目旨在进一步开发一种新的延长持续时间的局部麻醉剂配方来控制术后疼痛。拟议的创新将是现成的、随时可用的,并在给药后提供安全有效的局部麻醉,持续时间更长。它将以可注射生物可吸收凝胶的形式提供FDA批准的局部麻醉药布比卡因的长期释放。体外药物释放试验发现,该创新可提供布比卡因多天的持续释放。与两个临床标准对照组相比,拟议的创新提供了更高的麻醉水平(更长的爪子撤退潜伏期),持续时间更长。拟议的创新可能会为外科手术疼痛的局部治疗提供比目前临床选择更大的临床优势,如更好的麻醉/止痛效果、作用持续时间和新的直观给药途径。通过为术后急性疼痛提供安全有效的非阿片类药物治疗,这一配方有可能消除手术后对处方阿片类药物的需求。这一奖项反映了NSF的法定使命,并通过使用基金会的智力优势和更广泛的影响审查标准进行评估,被认为值得支持。
英文摘要
The broader impact/commercial potential of this I-Corps project is to provide a safe and effective non-opioid therapeutic for the control of post-operative pain that could eliminate the need for prescription opioids after surgery. Surgery is a critical point where patients are at risk of developing or worsening opioid-misuse disorders. The opioid crisis in the US and around the world is a significant public health concern. In the US, opioid overdoses have tripled since 1999, with the number of opioid prescriptions quadrupling. Prescription opioids are a major driver of addiction and adverse events. Current options for non-opioid local control of pain after a surgical procedure operation are limited. The public health implications of prescription opioids are significant, with 10% of patients going on to long-term use after surgery, and a cost of $78 billion to the United States health care system annually. Over 14,000 people die of prescription opioid misuse per year. As the number of procedures performed per year increases, and as outpatient surgery becomes more prevalent, improving control of post-operative pain can have a significant and increasing impact on rising health-care costs.This I-Corps project seeks to further develop a novel prolonged duration local anesthetic formulation for control of post-operative pain. The proposed innovation would be off-the-shelf, ready-to-use, and provide safe and effective local anesthesia for longer duration after administration. It will be in the form of an injectable bioresorbable gel that provides prolonged release of FDA-approved local anesthetic drug bupivacaine. In vitro drug release testing found that the innovation can provide a sustained release of bupivacaine for multiple days. The proposed innovation provided greater levels of anesthesia (greater paw withdrawal latencies) for a longer duration than both clinical standard control groups. The proposed innovation may provide significant clinical advantages over current clinical options for local management of surgical pain such as greater anesthetic/analgesic effect, duration of effect, and novel intuitive route of administration. This formulation has the potential to eliminate the need for prescription opioids after surgery by providing safe and effective non-opioid management of acute postoperative pain.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金